Clinical Trial Update: Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update on combining everolimus with a radiolabeled somatostatin analogue for neuroendocrine tumors across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• Everolimus (everolimus)
• radiolabeled somatostatin analogue

Snippet

Sponsor: King Faisal Specialist Hospital & Research Center | Conditions: Neuroendocrine Tumors | Phase 1, Phase 2 | Status: UNKNOWN